Abstract
Chronic spontaneous urticaria (CSU) affects a large number of people, affecting quality of life and daily activities.1 Omalizumab, a recombinant humanized anti–immunoglobulin E (IgE) monoclonal antibody, has been found to have efficacy in treating CSU, which might be through its ability to reduce the level of free IgE and subsequently reduce the expression of high-affinity receptor for the Fc region of IgE (FcεRI) on mast cells and basophils.2 In previous studies, more than half of the patients with CSU experienced rapid reductions of CSU severity within 1 week after the first dose of omalizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
